EP0668774A4 - Interleukin receptor targeted molecules for treatment of inflammatory arthritis. - Google Patents

Interleukin receptor targeted molecules for treatment of inflammatory arthritis.

Info

Publication number: EP0668774A4
Authority: EP; European Patent Office
Prior art keywords: treatment; inflammatory arthritis; targeted molecules; interleukin receptor; receptor targeted
Prior art date: 1991-05-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP19920912075

Other languages

German (de)

French (fr)

Other versions

EP0668774A1 (en

Inventor

Thasia G Woodworth

Jean C Nichols

Patricia A Bacha

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Seragen Inc

Original Assignee

Seragen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-03

Filing date

1992-05-04

Publication date

1995-04-25

1992-05-04 Application filed by Seragen Inc filed Critical Seragen Inc

1995-04-25 Publication of EP0668774A4 publication Critical patent/EP0668774A4/en

1995-08-30 Publication of EP0668774A1 publication Critical patent/EP0668774A1/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP92912075A 1991-05-03 1992-05-04 Interleukin receptor targeted molecules for treatment of inflammatory arthritis Withdrawn EP0668774A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US69548091A	1991-05-03	1991-05-03
US695480		1991-05-03
US87652192A	1992-04-30	1992-04-30
US876521		1992-04-30
PCT/US1992/003714 WO1992019259A1 (en)	1991-05-03	1992-05-04	Interleukin receptor targeted molecules for treatment of inflammatory arthritis

Publications (2)

Publication Number	Publication Date
EP0668774A4 true EP0668774A4 (en)	1995-04-25
EP0668774A1 EP0668774A1 (en)	1995-08-30

Family

ID=27105578

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP92912075A Withdrawn EP0668774A1 (en)	1991-05-03	1992-05-04	Interleukin receptor targeted molecules for treatment of inflammatory arthritis

Country Status (7)

Country	Link
EP (1)	EP0668774A1 (en)
JP (1)	JPH06510750A (en)
AU (1)	AU665763B2 (en)
BR (1)	BR9205967A (en)
CA (1)	CA2108886A1 (en)
NO (1)	NO933960L (en)
WO (1)	WO1992019259A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7608693B2 (en) *	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
NZ783258A (en)	2012-08-21	2023-06-30	Regeneron Pharma	Methods for treating or preventing asthma by administering an il-4r antagonist
TWI697334B (en)	2013-06-04	2020-07-01	美商再生元醫藥公司	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
TWI634900B (en)	2013-07-11	2018-09-11	再生元醫藥公司	Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
EP3110848B1 (en)	2014-02-28	2024-02-14	Regeneron Pharmaceuticals, Inc.	Methods for treating skin infection by administering an il-4r antagonist
EP3218412A1 (en)	2014-11-14	2017-09-20	Sanofi Biotechnology	Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
PT3506931T (en)	2016-09-01	2024-08-21	Regeneron Pharma	Methods for preventing or treating allergy by administering an il-4r antagonist
TWI784988B (en)	2016-12-01	2022-12-01	美商再生元醫藥公司	Methods of treating inflammatory conditions
US11053309B2 (en)	2017-08-04	2021-07-06	Regeneron Pharmaceuticals, Inc.	Methods for treating active eosinophilic esophagitis
PT3515465T (en)	2017-08-18	2024-03-04	Regeneron Pharma	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
KR102694419B1 (en)	2017-10-30	2024-08-09	사노피 바이오테크놀로지	Method for treating or preventing asthma by administering an IL-4R antagonist
CN112153982A (en)	2018-05-13	2020-12-29	瑞泽恩制药公司	Method for treating atopic dermatitis by administering an IL-4R inhibitor
MA55372A (en)	2019-03-21	2022-01-26	Regeneron Pharma	COMBINATION OF IL-4/IL-13 PATHWAY INHIBITORS AND PLASMOCYTE ABLATION TO TREAT ALLERGY
EP4010373A1 (en)	2019-08-05	2022-06-15	Regeneron Pharmaceuticals, Inc.	Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en)	2019-08-05	2022-11-22	Regeneron Pharmaceuticals, Inc.	Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992006117A1 (en) *	1990-09-28	1992-04-16	Seragen, Inc.	Inhibiting unwanted immune responses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE448386B (en) *	1978-10-18	1987-02-16	Sandoz Ag	NEW CYCLOSPORIN DERIVATIVES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
ES522315A0 (en) *	1982-05-12	1984-08-16	Harvard College	A PROCEDURE FOR OBTAINING A HYBRID PROTEIN.
US5080898A (en) *	1982-05-12	1992-01-14	The University Hospital	Enzymatically active toxin coupled to a cell-specific ligand
IL89504A0 (en) *	1988-03-08	1989-09-10	Univ Wyoming	Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same

1992
- 1992-05-04 JP JP4511998A patent/JPH06510750A/en active Pending
- 1992-05-04 CA CA002108886A patent/CA2108886A1/en not_active Abandoned
- 1992-05-04 AU AU19927/92A patent/AU665763B2/en not_active Ceased
- 1992-05-04 WO PCT/US1992/003714 patent/WO1992019259A1/en not_active Application Discontinuation
- 1992-05-04 BR BR9205967A patent/BR9205967A/en not_active Application Discontinuation
- 1992-05-04 EP EP92912075A patent/EP0668774A1/en not_active Withdrawn
1993
- 1993-11-02 NO NO933960A patent/NO933960L/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992006117A1 (en) *	1990-09-28	1992-04-16	Seragen, Inc.	Inhibiting unwanted immune responses

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
54TH ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, SEATTLE, WASHINGTON, USA, OCTOBER 27-NOVEMBER 1, 1990. ARTHRITIS RHEUM 33 (9 SUPPL.). 1990. S105. CODEN: ARHEAW ISSN: 0004-3591 *
55TH ANNUAL MEETING OF THE AMERICAN COLLEGE OF RHEUMATOLOGY, BOSTON, MASSACHUSETTS, USA, NOVEMBER 17-21, 1991. ARTHRITIS RHEUM 34 (9 SUPPL.). 1991. S89. CODEN: ARHEAW ISSN: 0004-3591 *
ARTHRITIS RHEUM 32 (4). 1989. 386-392. CODEN: ARHEAW ISSN: 0004-3591 *
CHEMICAL ABSTRACTS, vol. 114, no. 9, 4 March 1991, Columbus, Ohio, US; abstract no. 79863 *
CORY A. WATERS ET AL.: "INTERLEUKIN 2 RECEPTOR-TARGETED CYTOTOXICITY. RECEPTOR BINDING REQUIREMENTS FOR ENTRY OF A DIPHTHERIA TOXIN-RELATED INTERLEUKIN 2 FUSION PROTEIN INTO CELLS.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 20, pages 785 - 791 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; BACHA P ET AL: "IMPACT OF A SPECIFIC RECEPTOR-DIRECTED CYTOTOXIN DAB-486IL-2 ON RAT ADJUVANT ARTHRITIS." *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; FORTE S ET AL: "IMPACT OF A SPECIFIC RECEPTOR-DIRECTED CYTOTOXIN DAB-486IL-2 ON RAT ADJUVANT ARTHRITIS." *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; LAFFON A ET AL: "VERY LATE ACTIVATION ANTIGEN ON SYNOVIAL FLUID T CELLS FROM PATIENTS WITH RHEUMATOID ARTHRITIS AND OTHER RHEUMATIC DISEASES." *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; SEWELL K L ET AL: "IMPROVEMENT IN REFRACTORY RHEUMATOID ARTHRITIS BY INTERLEUKIN-2 RECEPTOR TARGETED THERAPY." *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; *
GOLDSMITH M.F.: "EXCITEMENT OVER IMMUNOMODULATION INUNDATES CLINICAL RESEARCH MEETINGS [NEWS]", JAMA, vol. 265, no. 21, 5 June 1991 (1991-06-05), pages 2768 - 2773 *
GRAILER ALAN P. ET AL.: "INHIBITION OF HUMAN ANTIGEN-SPECIFIC MEMORY B CELL RESPONSE IN VITRO BY A DIPHTERIA TOXIN-RELATED INTERLEUKIN 2 FUSION PROTEIN.", CELL. IMMUNOL., vol. 132, no. 2, pages 481 - 493, XP024001012, DOI: doi:10.1016/0008-8749(91)90044-C *
MEETING OF THE ASSOCIATION OF AMERICAN PHYSICIANS, THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, AND THE AMERICAN FEDERATION FOR CLINICAL RESEARCH, WASHINGTON, D.C., USA, MAY 4-7, 1990. CLIN RES 38 (2). 1990. 276A. CODEN: CLREAS ISSN: 0009-9279 *
See also references of WO9219259A1 *

Also Published As

Publication number	Publication date
NO933960L (en)	1993-12-28
NO933960D0 (en)	1993-11-02
AU665763B2 (en)	1996-01-18
EP0668774A1 (en)	1995-08-30
WO1992019259A1 (en)	1992-11-12
CA2108886A1 (en)	1992-11-04
JPH06510750A (en)	1994-12-01
BR9205967A (en)	1994-07-26
AU1992792A (en)	1992-12-21

Publication	Publication Date	Title
EP0603194A4 (en)	1994-12-07	Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis.
EP0668774A4 (en)	1995-04-25	Interleukin receptor targeted molecules for treatment of inflammatory arthritis.
EP0558317A3 (en)	1993-12-22	Cauterising apparatus
ZA93811B (en)	1993-09-10	Methods of treating inflammatory dermatoses.
EP0460912A3 (en)	1992-06-17	Medicaments for the treatment of sexual disorder
IL110204A0 (en)	1995-01-24	Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
SG43952A1 (en)	1997-11-14	Process for the purification of chlorofluorocarbons
EP0673384A4 (en)	1996-10-09	Polypeptides useful for treating inflammatory disorders.
GB2262036B (en)	1996-01-03	Medicaments for treating inflammatory conditions or for analgesia
EP0563239A4 (en)	1994-10-12	A truncated interleukin-1 receptor gene for the treatment of arthritis.
EP0510503A3 (en)	1993-03-17	Process for the treatment of surfaces
GB9420740D0 (en)	1994-11-30	Sequence of the hyaluronan receptor gene
DZ2012A1 (en)	2002-07-21	Benzamides for the treatment of neurological degenerations.
ZA929879B (en)	1993-07-02	Compositions for the treatment of mammalian diseases.
SG49017A1 (en)	1998-05-18	Polypeptides useful for treating inflammatory disorders
PH31659A (en)	1999-01-12	Therapeutic nucleotides.
GB9322120D0 (en)	1993-12-15	Purification of 1,1-dichloro-1-fluoroethane
HU911045D0 (en)	1991-10-28	Apparatus for the preloading of prefabricated bars
AU2959892A (en)	1993-06-15	Apparatus for thermal treatment of the prostate
EP0507458A3 (en)	1993-08-11	Process for the purification of 1,1,1,2-tetrafluoroethane
EP0584251A4 (en)	1995-08-02	Cytokine receptor targeted molecules for treatment of meoplastic cell growth.
FR2688001B1 (en)	1994-05-20	PROCESS FOR THE PREPARATION OF P-AMINOPHENOLS.
NO974956D0 (en)	1997-10-27	Therapeutic composition for arthritis
EP0609335A4 (en)	1994-10-12	Methods for the treatment of hyperlipidemia using azaspiranes.
GB2289046B (en)	1996-09-04	An effluent treatment system

Legal Events

Date	Code	Title	Description
1995-04-25	A4	Supplementary search report drawn up and despatched
1995-04-25	AK	Designated contracting states	Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1995-07-14	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
1995-08-30	17P	Request for examination filed	Effective date: 19931124
1995-08-30	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE
1997-05-14	17Q	First examination report despatched	Effective date: 19970402
1999-04-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
1999-06-09	18D	Application deemed to be withdrawn	Effective date: 19981210